Weatherly Asset Management L. P. held its position in Celgene Corporation (NASDAQ:CELG) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,582 shares of the biopharmaceutical company’s stock at the close of the second quarter. Weatherly Asset Management L. P.’s holdings in Celgene Corporation were worth $335,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Sowell Financial Services LLC boosted its position in Celgene Corporation by 0.5% during the first quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 13 shares during the last quarter. South Texas Money Management Ltd. boosted its position in Celgene Corporation by 0.6% during the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock worth $305,000 after acquiring an additional 15 shares during the last quarter. Flagship Harbor Advisors LLC boosted its position in Celgene Corporation by 0.9% during the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock worth $253,000 after acquiring an additional 18 shares during the last quarter. Keel Point LLC boosted its position in Celgene Corporation by 0.9% during the first quarter. Keel Point LLC now owns 3,103 shares of the biopharmaceutical company’s stock worth $386,000 after acquiring an additional 28 shares during the last quarter. Finally, First Heartland Consultants Inc. boosted its position in Celgene Corporation by 0.6% during the second quarter. First Heartland Consultants Inc. now owns 6,189 shares of the biopharmaceutical company’s stock worth $804,000 after acquiring an additional 35 shares during the last quarter. Hedge funds and other institutional investors own 79.33% of the company’s stock.

Shares of Celgene Corporation (NASDAQ CELG) opened at 142.97 on Thursday. The firm has a 50 day moving average of $135.45 and a 200-day moving average of $127.81. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $144.62. The stock has a market capitalization of $111.85 billion, a P/E ratio of 44.28 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. During the same period in the previous year, the company posted $1.44 earnings per share. The business’s revenue for the quarter was up 18.7% compared to the same quarter last year. Analysts forecast that Celgene Corporation will post $7.32 earnings per share for the current year.

CELG has been the topic of a number of recent research reports. Mizuho boosted their price target on shares of Celgene Corporation from $130.00 to $134.00 and gave the stock a “buy” rating in a research report on Thursday, June 1st. Canaccord Genuity set a $156.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a report on Tuesday, June 6th. Cann reiterated a “buy” rating on shares of Celgene Corporation in a report on Wednesday, June 7th. Oppenheimer Holdings, Inc. set a $148.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a report on Thursday, June 8th. Finally, BidaskClub upgraded shares of Celgene Corporation from a “strong sell” rating to a “sell” rating in a report on Wednesday, June 14th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $149.42.

In other news, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the transaction, the director now directly owns 85,551 shares in the company, valued at $12,110,599.56. The disclosure for this sale can be found here. Over the last three months, insiders have sold 46,233 shares of company stock worth $6,268,259. Corporate insiders own 0.95% of the company’s stock.

WARNING: “Celgene Corporation (CELG) Stake Held by Weatherly Asset Management L. P.” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/09/28/celgene-corporation-celg-stake-held-by-weatherly-asset-management-l-p.html.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.